Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd

Details Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd

1991-07-03

1999-12-14

Kunz, Gary L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

536 285, A61K 3170, C07H 1906

Patent

active

060018186

ABSTRACT:
This invention relates to the use of 2',3'-dideoxycytidin-2'-ene (2',3'-dideoxy-2',3'-didehydrocytidine) in treating patients infected with a retrovirus.

REFERENCES:
patent: 3817982 (1974-06-01), Verheyden et al.
patent: 4710492 (1987-12-01), Lin et al.
Schaeffer et al, Nature, 272, 583-585 (1978).
De Clercq et al, Biochemical Pharmacology 29 1849-1851 (1980).
Broder, "AIDS, Modern Concepts and Therapeutic Challenges", Marcel Dekker, Inc. (1987).
Mitsuya et al, Nature, 325, Feb. 26, 1987, pp. 773-777.
Balzarini et al, Molecular Pharmacology 32 162-167 (1987).
Robins, "Synthetic Antiviral Agents", C & En, Jan. 27, 1986.
Yarchoan et al, the Lancet, Jan. 16, 1988, pp. 76-80.
Fischl et al, The New England Journal of Medicine 317 No. 4 pp. 185-191 (1987).
Schaeffer et al, Nature 272 Apr. 13, 1978 pp. 583-585.
Mitsuya et al, Nature 325 Feb. 26, 1987, pp. 773-778.
Brodel, "AIDS, Modern Concepts and Therapeutic Challenges", Marcel Dekker, Inc. (1987).
De Clercq et al, Biochem. Pharma. 29 pp. 1849-1851 (1980).
Mitsuya et al, Proc. Natl. Aca. Sci USA 82, pp. 7096-7100 (1985).
Derwent Abstract No. 88-170966/25.
J. P. Horwitz, J. Chua, M. Noel, J. T. Donatti, J. Org. Chem., 32, 817 (1967).
H. Mitsuya and S. Broder, Proc. Natl. Acad. Sci. USA, 83, 1911-1915, Mar. 1986.
Effects of 2', 3'-Dideoxynucleosides on Mammalian Cells and Viruses pp. 402-408 (1984 M. Anwar Waqar et al).
Inibition of the in vitro infectivity andcytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides; Hiroaki Mutsuya and Samuel Broder vol. 83 pp. 1911-1915 Mar. 1986 Medical Sciences, Proc. Natl. Acad. Sci. USA.
The Anti-HTLV-III (Anti-HIV) and Cytotoxic Activity of 2', 3'-Didehydro-2', 3'-dideoxyribonucleosides: A Comparison with their Parental 2', 3'-Dideoxyribonucleosides Jan Balzarini et al; Mol. Pharmacol. 32(1) Jul. 1987 pp. 162-167.
Inhibition by 2', 3'-Dideoxythymidine of Retroviral infection of Mouse and Human Cells Philip Furmanski et al; Cancer Letters, 8 (1980) pp. 307-315.
Antiviral Activity of 2', 3'-Dideoxycytidin-2'-Ene (2', 3'-Dideoxy-2', 3'-Didehydrocytidine Against Human immunodeficiency Virus in Vitro Tai-Shun Lin et al Biochemical Pharmacology vol. 36 No. 3 pp. 311-316 1987.
Potent andSelective Anti-HTLV-III/LAV activity of 2', 3'-Dideoxycytidinene, the 2', 3'-Unsaturated Derivative of 2', 3'-Dideoxyctyidinee Jan Balzarine et al Biochem Biophys Res. Commun. vol 140 No. 2 1986 pp. 735-742.
Synthesis and Antitumor Activity of Cytosine and Adenine Nucleosides of unsaturated 5-(Aminoacyl)Aminopentofuranoses Carbohydrate Research 78 (1980) Takeshi Adachi et al pp. 67-77.
Lin et al, J. Med. Chem., 26 1691-1696 (1983).

Affiliated with

Also associated with

Rating

Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 2',3'-dideoxycytidin-2'-ene (2'- ,3'-dideoxy-2'3'-didehyd will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-863514